U.S. markets closed
  • S&P Futures

    4,412.00
    -3.00 (-0.07%)
     
  • Dow Futures

    34,980.00
    -18.00 (-0.05%)
     
  • Nasdaq Futures

    15,046.25
    0.00 (0.00%)
     
  • Russell 2000 Futures

    2,215.20
    -4.20 (-0.19%)
     
  • Crude Oil

    70.47
    -0.09 (-0.13%)
     
  • Gold

    1,817.30
    +3.20 (+0.18%)
     
  • Silver

    25.72
    +0.14 (+0.54%)
     
  • EUR/USD

    1.1878
    +0.0010 (+0.08%)
     
  • 10-Yr Bond

    1.1760
    +0.0020 (+0.17%)
     
  • Vix

    18.04
    -1.42 (-7.30%)
     
  • GBP/USD

    1.3929
    +0.0014 (+0.10%)
     
  • USD/JPY

    109.0490
    -0.0010 (-0.00%)
     
  • BTC-USD

    38,084.96
    -675.73 (-1.74%)
     
  • CMC Crypto 200

    930.39
    -13.05 (-1.38%)
     
  • FTSE 100

    7,105.72
    +24.00 (+0.34%)
     
  • Nikkei 225

    27,603.57
    -38.26 (-0.14%)
     

Company News for May 27, 2020

·1 min read
  • Shares of Evofem Biosciences, Inc. EVFM surged 16% after the clinical-stage biopharmaceutical company disclosed that the FDA had approved its birth control gel Phexxi.

  • Shares of Benefitfocus, Inc. BNFT soared 15.1% after the provider of cloud-based benefits management platform reported $80 million investment by BuildGroup LLC.

  • Shares of Sorrento Therapeutics, Inc. SRNE rose 3.9% after the clinical stage biopharma company received FDA IND clearance to initiate Phase I clinical trial of its CD38 antibody-drug conjugate (ADC) STI-6129.

  • Shares of Cellectar Biosciences, Inc. CLRB gained 7.1% after it received FDA fast track designation for CLR 131 in Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Benefitfocus, Inc. (BNFT) : Free Stock Analysis Report
 
Cellectar Biosciences, Inc. (CLRB) : Free Stock Analysis Report
 
Sorrento Therapeutics, Inc. (SRNE) : Free Stock Analysis Report
 
Neothetics, Inc. (EVFM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research